Loading…
Loading…
BSYI (BioSyntech, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
BSYI does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BSYI and 80,000+ other tickers.
See exactly how BSYI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BSYI and 80,000+ other tickers.
BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels aimed at both repairing tissues and delivering therapeutic compounds. The company's key product pipeline features BST-CarGel, a biodegradable gel designed for cartilage repair; BST-InPod, intended for alleviating heel discomfort; BST-DermOn, for managing and healing chronic wounds; BST-Ossifil, used in bone void filling; BST-Ossifix, which provides structural support for bones; and BST-Disc, focused on restoring intervertebral discs. Beyond these, BioSyntech offers injectable products leveraging BST-Gel technology…
No recent news available.